[1]Davis A,Godwin A,Lippman J,et al.Triphsic norgestimatc-ethnyl estradiol for treating dysfunctional uterine bleeding[J].Obstetrics Gynecology,2000,96
(6):913-920.
[2]van vliet HA,Grimes DA,Helmerhorst FM,et al.Biphasic versus triphasic oral contraceptives for contraception[J].Contraception,2002,65(5):321-324.
[3]Norambuena J,Bierschwale H.对敏定偶的避孕效果、月经周期控制和副作用的临床评价[J].中国计划生育学,2001,1(69):50-51.
[4]Mishell DR Jr.Oral contraceptive:Indication,contraindication,formulations,monitoring,In Management of Common Problems in Obstetrics and Gynecology
[M].Forth edition.Massachusetts:Blackwell Publishing,2002: 445-449.
[5]A.Albert Yuep,MD.Oral Contraception;Trend Oime[J]. J Reproductive Med,2002,47(11):967-973.
[6]王 霞,杨泉海.口服避孕药的安全性评价[J].首都医药,2003,10(04):26-28.
[7]Shulman LP.Oral contraceptives risk[J].Obste Gynecol Clin North Am,2000,27(4):695-704.
[8]赵 爽,郑建华.第3代孕激素口服避孕药的种类与应用[J].中国实用妇科与产科杂志,2005,21(1):6-8.
[9]拉丁美洲口服避孕药研究小组.口服避孕药敏定偶和妈富隆的临床效果比较[J].中国计划生育杂志,2001,9(5):309.